Gezegen, Hayreddin;Guerdere, Meliha B.;Dincer, Ayseguel;Oezbek, Oguz;Kocyigit, Uemit M.;Taslimi, Parham;Tuezuen, Burak;Budak, Yakup;Ceylan, Mustafa published 《Synthesis, molecular docking, and biological activities of new cyanopyridine derivatives containing phenylurea》 in 2021. The article was appeared in 《Archiv der Pharmazie (Weinheim, Germany)》. They have made some progress in their research.Reference of 3-Cyanopyridine The article mentions the following:
A new class of cyanopyridine derivatives containing the phenylurea unit was synthesized and tested against some metabolic enzymes including acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase (α-Gly). The new cyanopyridine derivatives showed Ki values in the range of 40.73 ± 6.54 to 87.05 ± 16.98μM against AChE, 29.17 ± 4.88 to 124.03 ± 22.43μM against BChE, and 3.66 ± 0.93 to 26.33 ± 5.05μM against α-Gly. These inhibition effects were compared with standard enzyme inhibitors like tacrine (for AChE and BChE) and acarbose (for α-Gly). Also, these cyanopyridine derivatives with the best inhibition score were docked into the active site of the indicated metabolic enzymes. Finally, mol. docking calculations were made to compare the biol. activities of the compounds against AChE (-8.81 kcal/mol for mol. 11d, I), BChE (-3.52 kcal/mol for mol. 11d), and α-Gly (-2.98 kcal/mol for mol. 11a, II). After mol. docking calculations, the ADME/T anal. was performed to examine the future drug use properties of the new cyanopyridine derivatives containing phenylurea. And 3-Cyanopyridine (cas: 100-54-9) was used in the research process.
3-Cyanopyridine(cas: 100-54-9) has been shown to have a number of pharmacological effects: it inhibits the production of prostaglandin E2 and nitric oxide in congestive heart failure patients; it prevents the formation of diazonium salt from benzene and nitrogen dioxide; it inhibits the growth of tumor cell lines; and it protects mice from radiation injury by scavenging reactive oxygen species. Reference of 3-Cyanopyridine